Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2024
Agile Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Agile Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: Hold
No price target forecast data available
Analyst Ratings
According to 1 stock analyst, the rating for Agile Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 18, 2024 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +231.13% | Sep 22, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +694.70% | Jun 26, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +694.70% | Jun 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $250 → $150 | Strong Buy | Maintains | $250 → $150 | +9,833.77% | Dec 30, 2022 |
Financial Forecast
Revenue This Year
37.58M
from 19.59M
Increased by 91.78%
Revenue Next Year
51.95M
from 37.58M
Increased by 38.26%
EPS This Year
0.80
from -6.71
EPS Next Year
1.12
from 0.80
Increased by 41.03%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 38.7M | 53.5M | |
| Avg | 37.6M | 52.0M | |
| Low | 36.1M | 49.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 97.4% | 42.3% | |
| Avg | 91.8% | 38.3% | |
| Low | 84.3% | 32.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.82 | 1.16 | |
| Avg | 0.80 | 1.12 | |
| Low | 0.76 | 1.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 45.2% | |
| Avg | - | 41.0% | |
| Low | - | 35.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.